Dr. Richard Gliklich, MD is the CEO of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.

Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices.

Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.

Dr. Gary Curhan, MD, ScD is the CMO of OM1, Inc. He is a practicing nephrologist in Boston.

Dr. Curhan has published widely on the epidemiology of many medical conditions including cardiovascular disease, hypertension, kidney stones, gout, hearing loss and others. His research in several large cohort studies, including the Nurses’ Health Studies and the Health Professionals Follow-Up Study, focuses on the prevention of common diseases by investigating scientifically and clinically important questions and exploring the role of modifiable factors and has been supported continuously for over 25 years by the National Institutes of Health.  He was the Editor-in-Chief of the Clinical Journal of the American Society of Nephrology, a leading nephrology journal. He has served on many national and international advisory committees, including the National Institutes of Health. He has mentored numerous individuals, many of whom now hold leadership positions at major academic institutions and public companies.

Dr. Curhan is a graduate of Brown University, Harvard Medical School and Harvard School of Public Health. Prior to joining OM1, he was a Professor of Medicine at Harvard Medical School and Professor of Epidemiology at Harvard School of Public Health.

Dennis Reilly is the Chief Financial Officer at OM1, Inc. Prior to joining OM1, he was the VP, Finance at Aptus Health, a global digital health company acquired by WebMD. Prior to Aptus, Dennis worked at several venture-backed healthcare technology companies.

Dennis began his career at Arthur Andersen as a CPA and corporate auditor. He received his BS from Merrimack College.

Madelyn is the Chief People Officer at OM1, Inc., where she leads the organization’s people
strategy, helping OM1 continue to build a community of diverse and high-performing talent and cultivate an inclusive, empowering and connected employee experience.

Prior to OM1, Madelyn was the Vice President of People at Kyruus, Inc. where she led the
People team’s efforts across Talent Acquisition, Talent Development, Employee Relations, Total Rewards, and Diversity, Equity, Inclusion & Belonging. Prior to Kyruus, Madelyn served as Senior Director, HR Business Partner and Head of Talent Development at Ascend Learning, an education technology company supporting students and educators in areas of Healthcare, Fitness & Wellness, and Safety & Security.

Before launching her career in human resources, Madelyn spent several years as an external consultant in areas of Talent Management / Development and Organizational Change, serving both multinational corporations as well as small businesses and non-profit organizations.

Madelyn received a BA in Psychology from Connecticut College and an MA in Social and
Organizational Psychology from Columbia University.

Dan Levy is the Chief Data Officer at OM1, Inc. In his role, Dan is responsible for developing and managing the partner ecosystem, with a focus on creating data solutions that generate value to both OM1 customers and partners.

For the prior 4 years, Dan was Chief Technology Officer at Amazing Charts, an ambulatory electronic medical record and health IT company. Dan led the software engineering, quality assurance, cloud operations, and data & analytics functions, and helped lead the company through an acquisition to Harris Healthcare. For the 8 years prior, Dan served as Vice President of Engineering and later as Chief Technology Officer at Outcome Sciences, a division of Quintiles, focusing on real-world and late phase research.  Prior to that, Dan held a number of technical leadership roles in both public and private, venture backed companies.

Dan received a BA in General Science from Brandeis University and an MS in Software Engineering from Boston University.

Eric Schrock is the Chief Technology Officer at OM1, Inc. In this role, he is responsible for the Product Engineering, Data Engineering, IT, and Security teams that develop and operate OM1's technology platform and products.

Prior to OM1, Eric was the Chief Technology Officer and Co-CEO at Jvion, a clinical AI company that uses prescriptive intelligence to improve patient outcomes. There, he ran the engineering, data science, professional services, and customer success teams responsible for product development and delivery. Prior to Jvion, Eric was VP of Engineering and CTO at Delphix, a data virtualization company that simplifies the delivery of secure production data to enterprise teams. Early in his career, Eric developed complex enterprise software systems including operating systems, filesystems, and hardware storage appliances.

Costas Boussios, PhD is the Chief Data Scientist at OM1, where he leads research and development of OM1's AI solutions. Prior to OM1, Dr. Boussios was the Chief Data Scientist at Mitra Capital LLC, the top performing equity market neutral fund of 2015. He has also led Data Science at Cignifi Inc, where he developed credit scoring solutions using mobile telephony data for millions of unbanked consumers in developing countries, and at Zakipoint Health LLC, where he developed patent-pending technology in optimization of health goal program engagement and adherence. He has also held the position of Director of Analytics at D&B working on commercial credit and insolvency risk scoring. Dr. Boussios holds a PhD from Mechanical Engineering at MIT with specialization in Machine Learning and Feedback Control Systems.

Dr. Carl Marci is the Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. Previously, he was Chief Psychiatrist and Chief Medical Officer at several venture backed health and technology companies.

Dr. Marci is board certified and is part-time staff at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School, he completed two NIH Fellowships in neuroscience and has published numerous articles in peer-review science journals. He holds seven patents and is author of a forthcoming book on the impact of technology on the brain.

Dr. Marci is a graduate of Columbia University and Oxford University where he was a Rhodes Scholar. He then went to Harvard Medical School and graduated with honors; he is also the former Director of Social Neuroscience at Massachusetts General Hospital.

Dr. Stefan Weiss is the Managing Director of Dermatology at OM1. A leader in the field of dermatology, his career has spanned both health care delivery and life sciences. Previously, he was Senior Medical Director at a publicly held dermatology focused biotech during which time he secured multiple new drug approvals for the treatment of inflammatory skin diseases.

Dr. Weiss is a board certified dermatologist. He has served on several national medical advisory committees and has published widely on psoriasis and atopic dermatitis.

Dr. Weiss is a graduate of Yale University. He received his MD and MHSc in Clinical Research from the Duke University School of Medicine. He completed residency training in dermatology at the Stanford University School of Medicine and a fellowship in Bioethics at the NIH. He holds an MBA from the Kellogg School of Management at Northwestern University.

Joseph Zabinski, PhD, MEM is Managing Director of AI & Personalized Medicine at OM1, where he oversees strategy and deployment of AI products across a range of use cases in partnership with pharmaceutical and medical device companies, providers, and health plans. Prior to joining OM1, Dr. Zabinski was a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Co. He specialized in advising life science and healthcare clients on using AI and advanced analytics, including identification of unmet medical needs, portfolio optimization, and AI strategy. His academic research focused on applications of Bayesian network modeling methods to predicting and stratifying environmental human health risk. Dr. Zabinski holds a master’s degree in engineering management from Dartmouth College, and a doctorate with a focus in health analytics from the School of Public Health at the University of North Carolina, Chapel Hill.

Kathryn is the Vice President of Real World Evidence at OM1. Previously, she was the Senior Director of Epidemiology and Outcomes Research at Outcome (now part of the late phase division of IQVIA).

Prior to Outcome, she served as lead for safety and risk management for products from clinical development through to post-marketing, with particular expertise in rare diseases, biologics and gene therapy applications at Genzyme. She has also held research positions at the NIH, Columbia and Harvard.

Kathryn is a graduate of Dartmouth College and the Harvard T.H. Chan School of Public Health.

Jess Paulus, is Vice President of Research at OM1 and leads a team of scientists with deep expertise in the designs and methods specific to leveraging real-world data networks to meaningfully inform clinical and regulatory decision making. Dr. Paulus provides senior scientific oversight regarding study design, analytic approaches, and dissemination strategies for RWD-based studies. 

Prior to joining OM1, Dr. Paulus was faculty at Tufts Medical School for over a decade, where she served as Research Director of the Tufts Predictive Analytics and Comparative Effectiveness Center and Associate Director of the Clinical and Translational Science MS/PhD Graduate Program. At Tufts, she led the conduct of federally-funded studies related to methods development in areas including comparative effectiveness research, clinical prediction models and heterogeneity of treatment effect. She also served on the faculty of the Harvard T.H. Chan School of Public Health and the Heller School at Brandeis University. 

Dr. Paulus graduated magna cum laude from Haverford College and received a doctorate in Epidemiology from Harvard T.H. Chan School of Public Health, where she focused on epidemiologic methods for the study of chronic disease using observational data. She remains engaged in teaching epidemiologic and RWD-methods as adjunct faculty at Tufts and as a lecturer at Harvard Medical School.

Andy DeMayo is Vice President and General Counsel at OM1, Inc. In this role, he is responsible for handling a wide range of legal issues, including those related to contracting and data privacy. Prior to joining OM1, he served as Senior Director in the Office of General Counsel at Quintiles, a global provider of product development and integrated healthcare services. In this role, he drafted and negotiated complex commercial contracts with biopharmaceutical companies, healthcare organizations, research sites, consultants and government agencies; and assisted with Quintiles’ trademark portfolio.

In previous roles, he worked as Senior Corporate Counsel for Outcome Sciences, Inc., In-House Counsel and Compliance Officer for Pioneer Behavioral Health (PHC, Inc.), and Corporate Counsel for Med Diversified Inc. Andy was a chapter co-author, contributor, and reviewer of the Agency for Healthcare Research and Quality handbook, “Registries for Evaluating Patient Outcomes: A User’s Guide,” and he co-authored a chapter in the Health Law & Compliance Update (2013 Edition).

Andy is a graduate of Boston College Law School and earned his bachelor’s degree from Tufts University. Outside of the office, he enjoys golfing, collecting vinyl records, and spending time with his family.

Tom Engel is the Vice President of Business Development for OM1, Inc. Previously, Tom led the US Sales Team for QuintilesIMS Real World Evidence following the merger of Quintiles and IMS Health. Prior to the merger, Tom led the North America Sales Team for Real World and Late Phase Research at Quintiles (NYSE: Q), the world's largest Clinical Research Organization (CRO). In 2004, Tom joined Rich Gliklich at Outcome Sciences, Inc. (Outcome) where he focused on sales and market development through the 2011 acquisition of Outcome by Quintiles.

In 1998, Tom joined Phase Forward (later acquired by Oracle) as the first Product Manager for InForm, the market-leading electronic data capture system for clinical development. He joined IntraLinks, Inc. in 2002 as Vice President of Strategic Business Development tasked to develop new sales channels for IntraLinks’ clinical products.

Tom received his Bachelor of Arts degree from Boston College in Mathematics a very long time ago. When not at home with his family, Tom can be found walking in the woods or on the nearest mountain.

As the VP of Marketing and Communications at OM1, Inc, Renee Hurley oversees strategy and implementation of the marketing, communications, and thought-leadership programs. Prior to joining OM1, Renee led the global marketing strategies, initiatives and teams for Quintiles Integrated Healthcare Services (IHS), which included Real-World & Late Phase Research, Commercial, Health Engagement & Communications, Advisory Services, and Payer & Provider business units.

In previous roles, Renee oversaw real-world research and provider marketing, communications and thought-leadership for Outcome Sciences Inc., worked in a variety of marketing roles for primary care and specialty conferences at MC Communications, and was a media researcher at MediaMap. She is an alumni of Boston University and enjoys exploring the world and hiking with her family.